Clinical trials: Acute Rejection of Renal Transplant
Rejection of Kidney Allograft
Blood Biomarkers in Pediatric Kidney Transplant Recipients
The objective of the proposed study is to assess whether a blood biomarker can be used to monitor the response to rejection treatment in pediatric kidney transplant recipients with biopsy-proven acute cellular or antibody…
- Trial name
- Omnigraf (NCT05477082)
- Testing
- Observational group
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Minnesota
Kidney Transplantation
Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal
Current therapy to prevent organ rejection relies on the use of calcineurin inhibitors either cyclosporine or tacrolimus. Although these agents have been very successful in preventing early acute rejection, this success has not…
- Trial name
- NCT00896012
- Testing
- Kidney Biopsy, Rapamune (sirolimus/rapamycin), Tacrolimus
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University at Buffalo
Transplant Recipient (Kidney), Primary Kidney Transplantation
Posttranslationally Modified Fetuin-A in Urine as a Marker for Renal Dysfunction (Patients With Chronic Kidney Disease - With or Without Kidney Transplantation).
Kidney transplantation is the preferred treatment method for patients with chronic kidney disease. Standard parameters (estimated glomerular filtration, albuminuria) of renal function detection are limited by many factors…
- Trial name
- (uPTM-FetA) (NCT06950931)
- Testing
- uPTM-FeA
- Where
- Slovakia
- Volunteers
- 86 people
- Sponsor
- University Hospital, Martin
Delayed Graft Function, Renal Outcome After Kidney Transplantation
Volatile Anesthetic Protection Of Renal Transplants 2
To compare the effect of a sevoflurane based anesthesia versus a propofol based anesthesia on the incidence of DGF in recipients of kidneys of donation after circulatory death (DCD) and donation after brain death (DBD) donors
- Conditions
- Delayed Graft Function, Renal Outcome After Kidney Transplantation, Acute Rejection (AR) of Transplanted Kidney, Graft Survival
- Trial name
- VAPOR-2 (NCT02727296)
- Testing
- sevoflurane, propofol
- Where
- 5 sites in Denmark, Netherlands and 2 more
- Volunteers
- 488 people
- Sponsor
- University Medical Center Groningen
Renal Failure
Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant
The purpose of this study is to evaluate the pharmacokinetics of LCP-Tacro tablets administered once-daily compared to Prograf capsules administered twice-daily after kidney transplantation.
- Trial name
- NCT01666951
- Testing
- LCP-Tacro tablets, Prograf
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Veloxis Pharmaceuticals
Renal Transplant Rejection
Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes
The goal of this observational study is to determine phenotypic, transcriptional, and epigenetic underpinnings of renal allograft rejection in renal transplant rejection.
- Trial name
- NCT06438107
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Pittsburgh
Kidney Transplantation
Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation
Primary purpose of this study is to compare renal function between subjects receiving optimized dose Advagraf® over 52 weeks after kidney transplantation and subjects receiving standard dose Advagraf®.
- Trial name
- OPTIMIZE (NCT02161237)
- Testing
- Advagraf®
- Where
- 2 sites in South Korea, Taiwan
- Volunteers
- 73 people
- Sponsor
- Astellas Pharma Inc
Kidney Transplantation, Host vs Graft Reaction
Renal Transporters After Renal Transplantation
Previous studies in animals revealed, that the activity of certain transporters along the nephron is changed with acute rejection after renal transplantation.
- Trial name
- NCT00427024
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital Muenster
Acute (Cellular) Renal Allograft Rejection
Single Dose rATG for Renal Allograft Rejection
Rabbit antithymocyte globulin (rATG) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous…
- Trial name
- NCT02102854
- Testing
- rATG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Methodist Hospital Research Institute
Kidney Transplantation
Regimen Optimization Study
Patients who undergo a kidney transplant require prolonged therapy with drugs that suppress the immune system (called immunosuppressive regimens) to stop the immune system from attacking the transplanted kidney in order to limit…
- Trial name
- NCT02137239
- Testing
- Thymoglobulin, Belatacept, mycophenolate mofetil(MMF)
- Where
- 20 sites in United States, Argentina
- Volunteers
- 58 people
- Sponsor
- Bristol-Myers Squibb
Kidney Transplant Immunosuppression
The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient
The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.
- Trial name
- NCT01424345
- Testing
- adjustment of immunosuppressant dosages, adjustment of the dosages of immunosuppressants
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- CAMC Health System
End Stage Renal Disease, Reperfusion Injury
Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function
The purpose of this study is to investigate local activation of the coagulation system in the kidney graft during organ preservation and during early reperfusion in adult kidney transplantation.
- Conditions
- End Stage Renal Disease, Reperfusion Injury, Delayed Graft Function, Kidney Transplantation
- Trial name
- KTX (NCT02568696)
- Where
- Finland
- Volunteers
- 100 people
- Sponsor
- Helsinki University Central Hospital
Renal Transplant Rejection
The Effect of Rituximab on the Development of Anti-Donor Antibodies
The aim of the study is to find out if Rituximab, which is an antibody against specific white cells involved in rejection, when combined with standard anti-rejection treatment can more effectively reverse the rejection process.
- Trial name
- NCT00695097
- Testing
- Rituximab, No Rituximab
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of California, San Francisco
Acute Rejection
Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients
Acute kidney allograft rejection is the major cause for a loss of graft function and has a negative impact on long-term graft survival.
- Trial name
- RIACT (NCT01117662)
- Testing
- Rituximab
- Where
- 14 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Hannover Medical School
Allografts, Rejection; Transplant, Kidney
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
The purpose of this study is to evaluate the efficacy, safety and tolerability of dual costimulation blockade with VIB4920 in combination of belatacept in adult male or female recipients of a renal allograft from a deceased…
- Conditions
- Allografts, Rejection; Transplant, Kidney, Transplant Rejection, Kidney Transplantation
- Trial name
- NCT04046549
- Testing
- Belatacept, VIB4920, Thymoglobulin
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Amgen
Kidney Tansplant, Acute Rejection (AR) of Transplanted Kidney
Daratumumab for Late Antibody-Mediated Rejection
The study titled "Daratumumab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients with De Novo Donor-Specific Antibodies" (DARTABMR) is a case-control investigation assessing whether daratumumab is more effective…
- Trial name
- DARTABMR (NCT07081126)
- Testing
- Daratumumab (Subcutaneously), control group
- Where
- Slovakia
- Volunteers
- 20 people
- Sponsor
- University Hospital, Martin
Renal Transplant Rejection, Pediatric Kidney Disease
VIRTUUS Children's Study
The objective of the VIRTUUS Children's Study is to adapt identified and validated adult noninvasive diagnostic and prognostic biomarkers for the characterization of allograft status in pediatric recipients of kidney allografts.
- Conditions
- Renal Transplant Rejection, Pediatric Kidney Disease, End Stage Renal Disease, Nephropathy
- Trial name
- VIRTUUS (NCT03719339)
- Where
- 13 sites in United States, Canada
- Volunteers
- 445 people
- Sponsor
- Children's Hospital of Philadelphia
Kidney Transplantation, Graft Rejection
A Study on a New Staining Method (C4d Staining) of Transplanted Kidney Biopsies
Patients who had received kidney transplantation may suffer from rejection. Recently, positive staining for C4d in kidney biopsies of malfunctioning transplant kidney is increasingly recognized as an important prognostic…
- Trial name
- NCT00498095
- Testing
- Renal biopsy
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Hospital Authority, Hong Kong
Short-term Graft Function, Metabolic Effects
Amino Acid Infusion in Kidney Transplant Recipients
The study addresses the impact of amino acid infusion in the early post-transplant period on graft function and the incidence of post-transplant complications.
- Conditions
- Short-term Graft Function, Metabolic Effects, Nutritional Effect, Immunological &Amp; Inflammatory Markers
- Trial name
- AID-KT (NCT06929637)
- Testing
- Infusion Therapy, Saline solution infusion
- Where
- Slovakia
- Volunteers
- 100 people
- Sponsor
- University Hospital, Martin
Graft Failure, Death
European Transplant Registry of Senior Renal Transplant Recipients on Advagraf
SENIOR transplant Registry European transplant registry of senior renal transplant recipients (above the age of 65 years) receiving initial immunosuppression with tacrolimus once daily, mycophenolate and steroids to investigate…
- Conditions
- Graft Failure, Death, Acute Rejection of Renal Transplant, Infections
- Trial name
- SENIOR (NCT02558452)
- Testing
- Tacrolimus once daily (Advagraf)
- Volunteers
- 1,000 people
- Sponsor
- Klemens Budde